| Wednesday, November 6, 2024 | |||
|---|---|---|---|
| KCA Mentorship Meeting (by invitation only) | 2:00 PM - 6:30 PM | Wheat | Sponsored by Pfizer. Moderator: Salvatore La Rosa, PhD |
| Thursday, November 7, 2024 | |||
| KCA Mentorship Meeting (by invitation only) | 8:00 AM - 12:00 PM | Wheat | Sponsored by Pfizer. Moderator: Salvatore La Rosa, PhD |
| AKCI Mentorship Lunch and Meeting (by invitation only) | 12:00 PM - 4:00 PM | Commonwealth 1 | Moderator: Brian Rini, MD, FASCO |
| Think Tank Meeting | 1:00 PM - 4:00 PM | Wheat | By invitation only. Sponsored by Exelixis. |
| Registration Desk Open | 1:00 PM - 6:00 PM | 2nd Street Pre-function Hallway | |
| Pre-clinical/ Translational Session 1 | 4:00 PM - 5:15 PM | Commonwealth Ballroom 2 & 3 | The session will cover the RCC Therapeutic Landscape: preclinical models, emerging new therapeutics with a path to the clinic. Chairs: Qing Zhang, PhD, M. Celeste Simon, PhD
Targeting the Dysfunctional SCL1A1/EAAT3 Transporter in Kidney Cancer: Abhishek Charkraborty, PhD
Targeting Acquired Resistance to HIF2⍺ Inhibition in Kidney Cancer: Qing Zhang, PhD Presenter has requested their slides not be posted
Biological Insights from Resistance Mechanisms: James Brugarolas, MD, PhD
Moderated Q & A |
| Pre-clinical/ Translational Session 2 | 5:30 PM - 6:45 PM | Commonwealth Ballroom 2 & 3 | This session will focus on RCC Genetic Evolution in Primary Tumor and Metastasis, advanced models and analyses to identify innovative drug modalities. Chairs: Marie Carlo,MD, Samra Turajlic, MD
Presenter has requested their slides not be posted
Q&A and Wrap- Up |
| KCA Clinical Advisory Board Meeting (invitation only) | 6:00 PM - 8:00 PM | Wheat | Moderators: Lauren Wood, RN, MSN, OCN Nancy Moldawer, RN, MSN |
| Faculty Networking Event | 8:30 PM - 10:00 PM | Rooftop | By invitation only. Sponsored by Pfizer. |
| Friday, November 8, 2024 | |||
| Rise & Shine Yoga | 6:00 AM - 7:45 AM | Copper | Sponsored by Genentech. Due to overwhelming response, two sessions will be held. The first is 6:00-6:45AM and second 7:00-7:45AM. |
| Registration Desk Open | 6:30 AM - 6:15 PM | 2nd Street Pre-function Hallway | |
| Young Investigators Session/ Breakfast | 7:00 AM - 8:00 AM | Commonwealth Ballroom 2 & 3 | Sponsored by Pfizer. Moderators: Tian Zhang, MD, MHS, Lauren Meehos Machos, MPH Expert Panelists: Brian Rini, MD, FASCO Ramaprasad Srinivasan, MD, PhD Dharanija Rao Chandler Park, MD, FACP This session invites early-career healthcare professionals to discuss career opportunities in kidney cancer across academia, industry, private practice, and research. Engage with both emerging and experienced experts to exchange insights, experiences, and challenges, enriching your professional journey in the kidney cancer field. |
| Exhibits & Posters | 7:30 AM - 5:00 PM | Commonwealth 6-8 | |
| Session 1 Panel Discussion: 'Inoperable' Kidney Cancer | 8:10 AM - 9:30 AM | Commonwealth 4-5 | Moderators: Stephanie Berg,DO, Jodi Maranchie, MD
Renal vein/thrombosus Involvement: Steven Chang, MD
SAbR for Locally Advanced and Unresectable Primary RCC: Raquibul Hannan, MD, PhD
Surveillance, Neoadjuvant / Palliative Treatment?: Leonard Appleman, MD, PhD
Panel with cases and panel discussion.
|
| SESSION 2: Expanding Supportive Care Options to Improve the Patient Experience and Outcomes Before, During, and After Therapy | 9:30 AM - 10:30 AM | Commonwealth 4-5 | Moderators: Sarah Psutka, MD. MS, Viraj Master, Md, PhD, FACS
Patient Perspective: Sid Sadler
Integrative Oncology in Kidney Cancer: Viraj Master, MD, PhD, FACS
Resilience Treatment & Burden Background Mindfulness/Wellness-based/Nutritional Interventions / Practices for Symptom / Toxicity Management: Anna Bausum, ND
Management of Sleep, Fatigue, Distress from a Cognitive Neuroscience Perspective: David Sheppard, PhD/Sarah Psutka, MD. MS
Exercise as Medicine: Hanna Hunter, MD
Wrap-up: Highlights, CAM Trials: Sarah Psutka, MD, MS
Moderated Q & A |
| Coffee Break | 10:30 AM - 10:50 AM | Commonwealth 6-8 | |
| SESSION 3: Divergent Histology in Kidney Cancer | 10:50 AM - 11:50 AM | Commonwealth 4-5 | Moderators: Jodi Maranchie, MD, Phillip M. Pierorazio, MD
Chromophobe Renal Cell Carcinoma: Novel Therapeutic Targets: Elizabeth (Lisa) Henske, MD, PhD
Presenter has requested their slides not be posted
WHO Definitions Divergent Path: Ying-Bei Chen, MD
Current Options for RCC with Divergent Histology: Bradley McGregor,MD
Ongoing Trials & Trials in the Pipeline: Benjamin Maughan, MD
Moderated Q&A |
| SESSION 4: Oral Abstracts | 11:50 AM - 12:50 PM | Commonwealth 4-5 | Moderators: Priyanka Chablani, MD, Wenxin (Vincent) Xu, MD Poster Ads
Blood-based multiomics profiling reveal immune features associated with response to immune checkpoint inhibitor (ICI) in patients with metastatic renal cell carcinoma (mRCC): Moshe C. Ornstein
99mTc-Sestamibi SPECT/CT for the Characterization of Solid Renal Masses: Secondary Endpoint Analysis of a Prospective Study Correlating Imaging to Histopathology Results: Aboubacar Kaba, MD
Body weight trajectories in patients with localized renal cell cancer: Linnea Olsson, PhD
Occurrence of local recurrences and metastases after ablative therapy versus partial nephrectomy of renal cell carcinoma: a real-world competing risk analysis: Prof Börje Ljungberg
Oral Abstracts
Clonal Origin of Belzutifan-Resistant Kidney Tumors in VHL Disease: Alejandro Sanchez
Transcript-Level Analysis Reveals Alternative Splicing and Isoform Switches in ccRCC: Implications for Progression and Survival: Chinaza Nnam
TRAVERSE: Updated safety and efficacy of ALLO-316 in advanced/metastatic clear cell renal cell carcinoma (ccRCC): Ritesh Kotecha
Validating Metastatic Organotropison of FGD1 Splice Varient in Clear Cell Renal Cell Carcinoma: Mitchell Hayes
Moderated Q & A |
| Lunch | 12:50 PM - 2:10 PM | Commonwealth 6-8 | Grab lunch from the Exhibit Hall and bring it with you to the Merck industry session in Commonwealth 2-3. |
| Non-CME Symposium spnosored by Merck: Patient Case-Based Learning: Clinical Management of Certain Adult Patients With Advanced RCC | 1:00 PM - 2:00 PM | Commonwealth 2-3 | Learning Objectives: •Understand clinical considerations for certain previously treated adult patients with advanced renal cell carcinoma. •Review clinical data on a treatment option and how to sequence through a hypothetical patient case. •Discuss how to monitor and manage potential adverse reactions through a hypothetical patient case.
Thai Ho, MD. has been caring for patients affected by genitourinary cancers for over 10 years. His expertise and the focus of his research is in treating kidney and bladder cancers. He also sees patients with kidney, bladder, upper tract urothelial, and prostate cancers, as well as patients affected by hereditary cancer syndromes. Dr Ho completed the Baylor College of Medicine Physician Scientist Program in 2006, internal medicine residency at Washington University in St. Louis in 2009, and Medical Oncology Fellowship at MD Anderson Cancer Center in 2012. At MUSC Hollings Cancer Center, Dr Ho is an Associate Professor, the Director of Precision Medicine, the Blatt-Ness Distinguished Endowed Chair in Cancer Research and a member of the Clinical Advisory Council for the VHL Alliance. Dr Ho comes to MUSC from the Mayo Clinic where he was an Associate Professor and a member of the Center for Individualized Medicine Epigenomics Group, Genomic Tumor Board, and von Hippel-Lindau Clinic. Grab lunch and bring it the session. |
| Break | 2:00 PM - 2:10 PM | Commonwealth 4-5 | |
| Session 5 Keynote Speaker | 2:10 PM - 2:40 PM | Commonwealth 4-5 | Introduction: Stephanie Berg, DO Keynote: Targeting Metabolism: Beating Kidney Cancer at Its Own Game: M. Celeste Simon, PhD |
| Christopher G. Wood Rising Star Award | 2:40 PM - 2:55 PM | Commonwealth 4-5 | Introduction: Bradley C. Leibovich, MD
Award Recipient: David Braun, MD, PhD
|
| SESSION 6: Going Beyond RECIST (Radiomics in Kidney Cancer) | 2:55 PM - 3:55 PM | Commonwealth 4-5 | Moderators: Yousef Zakharia, MD, Andrew Smith, MD, PhD
Traditional Imaging Modalities: Andrew Smith, MD, PhD
Challenges in Radiographics in Response to (Limitations of RECIST in Metastatic Setting): Simon Lo, MD, ChB, FACR, FASTRO
Validation with the Machine Learning Algorithms: Irbaz Riaz, MD
Moderated Q & A |
| Coffee Break | 3:55 PM - 4:05 PM | Commonwealth 6-8 | |
| SESSION 7: Mentorship Awards | 4:05 PM - 4:55 PM | Commonwealth 4-5 | Moderator: Brian Rini, MD, FASCO
SETD2 Deficiency Confers Sensitivity to BCL-XL Inhibition: Aguirre De Cubas, PhD
Presenter has requested their slides not be posted
Investigating Decoy-Resistant IL-18 Plus Immune Checkpoint Inhibitors in Renal Cell Carcinoma + Moderated Q & A: David Schoenfield, MD, PhD
Development of CA9-Targeted Radiopharmaceutical Agents for Kidney Cancer Theranostics: Reinier Hernandez, PhD
Metabolic Transitions Governing Disease State in Clear Cell Renal Cell Carcinoma: Shuchi Gulati, MD, MS
Presenter has requested their slides not be posted
|
| SESSION 8: Women & Allies in RCC: The Importance of Mentorship & Determining Your Career Path | 5:00 PM - 6:00 PM | Commonwealth Ballroom 2 & 3 | Moderators: Tian Zhang, MD, HHS, Ulka Vaishampayan, MD Panelists: Julie Gralow, MD, FASP, FASCO, Naomi Haas, MD, Helen Moon, MD, Fatima Rangwala, MD, PhD, ELIzabeth (Lisa) Henske, MD, PhD |
| Women & Allies in RCC: Continuing the Conversation Networking Reception | 6:00 PM - 6:30 PM | Old Louisville | Join Women in RCC members and others for a drink and light snacks to continue the conversation following Friday’s WiRCC session. |
| Networking Reception | 6:00 PM - 7:00 PM | Commonwealth 6-8 | |
| Poster Tour | 6:30 PM - 6:50 PM | Commonwealth 6-8 | Guides: Arpita Desai, Priyanka Chablani Meet in the Exhibit Hall |
| CME Symposium Presented by Peerview: Smart Steps for Effective Real-World Care in RCC: Enhancing Outcomes In Advanced Disease | 7:15 PM - 8:15 PM | Commonwealth 2-3 | Presenters: Sumanta Pal, Nizar Tannir, and Tian Zhang Key Reasons to Attend |
| Saturday, November 9, 2024 | |||
| Medical Steering Committee | 7:00 AM - 8:00 AM | Barrel | By invitation only. |
| Registration Desk Open | 7:30 AM - 11:00 AM | 2nd Street Pre-function Hallway | |
| Exhibits & Posters | 7:30 AM - 11:00 AM | Commonwealth 6-8 | |
| Session 9 KCA Updates, Committee Recognition & Tumor board - Management of the SRM | 8:00 AM - 9:10 AM | Commonwealth 4-5 | KCA Updates: Salvatore LaRosa, PhD
IKCSNA24 Committee Recognition
Moderators: Phillip M. Pierorazio, MD, Brian Shuch, MD DEBATE Triggers for Intervention for Patients on Active Surveillance: Tumor Size, Tumor Growth Rate, Tumor Histology: Maxine Tran, MD, Erick Kauffman, MD, Brian Shuch, MD
Tumor Board: Suzanne Merrill, MD, FACS, Joseph Panaro, MD, Adam Olson, MD, Maxine Tran, MD
|
| SESSION 10: Patient-Centered Outcomes in Kidney Cancer Research | 9:10 AM - 10:00 AM | Commonwealth 4-5 | Moderators: Dena Battle, Dan Geynisman, MD Patient Perspective COA: Katie Coleman
Measuring and Mitigating Decision Regret in the Management of Kidney Cancer: Sarah Psutka, MD, MS
Disease Burden in Renal Cell Carcinoma: Dena Battle
Financial Toxity and QoL: David Cella, PhD
Moderated Q & A |
| Coffee Break | 10:00 AM - 10:15 AM | Commonwealth 6-8 | |
| SESSION 11: Oral Abstracts | 10:15 AM - 11:00 AM | Commonwealth 4-5 | Moderators: Marie Carlo, MD, Yousef Zakharia, MD A Phase I/ II Trial of Pazopanib (Paz) Alternating (alt) with Bevacizumab (Bev) in Treatment-naïve Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) Patients (pts): Phase II results: Saby George, MD
CANINE: Prospective Comparison of Contrast-Enhanced Computed Tomography Against 89-Zr-TLX250 PositroN Emission Tomography/Computed Tomography for the Imaging-Based DetectioN of REcurrent Clear Cell Renal Cell Carcinoma After Surgery: Brian Shuch, MD
Characterization of the Safety Profile of Belzutifan in Patients With Renal Cell Carcinoma (RCC): A Pooled Analysis of 4 Clinical Trials: Pooja Ghatalia, MD
Phase 1 Study of Sitravatinib Combined with Nivolumab and Ipilimumab in Patients with Advanced Clear Cell Renal Cell Carcinoma: Clinical Outcomes and Translational Correlatives: Pavlos Msaouel, MD
|
| SESSION 12: Beyond IO and TKI | 11:00 AM - 12:00 PM | Commonwealth 4-5 | Moderators: Manojkumar Bupathi, MD, MS, Sumanta (Monty) Kumar Pal, MD, FASCO
HIF-2alpha: Kevin Courtney, MD, Phd
Other Checkpoint Drugs: Naomi Haas, MD
CAR-T Therapy: Ben Garmezy, MD
Vaccines: Elizabeth (Betsy) Plimack, MD, MS
Moderated Q & A |
| SESSION 13: WoodFire | 12:00 PM - 12:45 PM | Commonwealth 4-5 | Moderators: Brian Rini, MD, FASCO, Brad Leibovich, MD Panelists: Jose Karam, MD, FACS, Dan Geynisman, MD, Stephanie Berg, DO, E. Jason Abel, MD, FACS |
| SESSION 14: Awards Presentation | 12:45 PM - 1:10 PM | Commonwealth 4-5 | Introduction of Eugene P. Shonfeld Award Winner: Stephanie Berg, DO
Eugene P. Shonfeld Award Winner & Lecturer: Naomi Haas, MD
Introduction of Nicholas J. Voglezang Humanitarian Award Winner: Tian Zhang, MD
Nicholas J. Vogelzang Humanitarian Award Winner & Lecturer: Daniel J. George, MD
|
| Closing Comments | 1:10 PM - 1:15 PM | Commonwealth 4-5 | Closing Comments from Co-Chairs: Stephanie Berg, DO, Jodi Maranchie, MD |
| Grab & Go Lunch | 1:15 PM - 1:30 PM | Commonwealth 4-5 | Thank you for attending IKCSNA24! A grab and go lunch available outside the general session room as you leave. |
| KCA Board of Directors Meeting | 2:00 PM - 5:00 PM | Barrel | By invitation only. |